AI-developed compound linked to younger biological age in small trial
Early trial data hints that an AI-designed drug may lower biological age markers, though the study was limited in size and scope.
A drug created through artificial intelligence by the biotech firm Insilico Medicine has shown preliminary signs of reversing biological aging in a small human study. The findings, reported in Nature Biotechnology, focused on rentosertib, a molecule developed using the company's AI platform to target aging-related pathways. Researchers measured aging through several molecular biomarkers rather than chronological age.
In the trial, which involved 42 participants, six separate aging clocks indicated that individuals who received the drug appeared biologically younger by as much as six years compared to those given a placebo. These clocks analyze patterns like DNA methylation to estimate the body's physiological state. The results suggest rentosertib may influence fundamental processes tied to cellular deterioration, though the exact mechanisms remain under investigation.
Experts caution that the study's small participant count and the lack of testing in healthy populations mean the results are far from conclusive. The drug has not yet been evaluated for broader safety or efficacy in preventing age-related disease. Further trials will be needed to determine whether the observed effects hold up in larger, more diverse groups and translate into meaningful health outcomes.